Health
FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.
OriginalSourceBusinessLineIndiaLeanUnratedCredibilityUnratedPublished07:01 UTCSourceBusinessLineIndiaLeanUnratedCredibilityUnratedPublished07:01 UTC
“FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning”
“These drugs may be associated with a drop in blood flow to the optic nerve which can cause sudden, painless loss of vision in one eye, and sometimes the damage is permanent, FDA said”
FDA adds warning for GLP-1 drugs citing possible NAION risk
Key points
- FDA requires all GLP-1 receptor agonists to add warnings for NAION, a rare eye condition.
- NAION can cause sudden, painless vision loss and may be permanent.
- Meta-analysis: 15 probable NAION cases among 134,253 participants; GLP-1 users 6.4 per 100,000 person-years.
- Real-world study: no risk rise versus SGLT-2 inhibitors; higher risk vs DPP-4 inhibitors.
- Regulatory stance: evidence suggests possible increased risk but does not prove causation.
Other reports
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
- SourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at MintSourceMintIndiaOwner: HT MediaLeanCenterCredibilityRatings: AllSides, MBFCRead at Mint
- SourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars TechnicaSourceArs TechnicaUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at Ars Technica
“GLP-1 drugs may increase risk of vision loss from rare condition, FDA warns”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The NationalSourceThe NationalUnited Arab EmiratesLeanUnratedCredibilityUnratedRead at The National
“FDA orders new warning on GLP-1 drugs over potential risk of blindness”
- SourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global NewsSourceGlobal NewsCanadaOwner: Global Television NetworkLeanUnratedCredibilityUnratedRead at Global News
- SourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBCSourceBBCUnited KingdomOwner: British Broadcasting CorporationLeanCenterCredibilityRatings: AllSides, MBFCRead at BBC
“Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness”
- SourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The GuardianSourceThe GuardianUnited KingdomOwner: Guardian Media GroupLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Guardian
“FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications”
How it got here
BusinessLine publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 8.
The Brief ranks it 8th.
8 8 FDA warns GLP-1 weight loss medications can cause rare blindness-causing eye condition.
FDA reviewed 126 trials and found 15 probable NAION cases, with rates higher among users than controls.